NEUPHORIA THERAPEUTICS INC

NEUPNASDAQ

🏆 #4350 by market capEarnings Sep 2US Equity

$3.84▲ $0.03 (+0.66%)

Live

1h▲ 0.7%

24h▲ 0.7%

7d▼ 2.5%

14d▲ 0.9%

30d▲ 10.2%

1y▼ 47.0%

🏦Market Cap

$21M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

104.8%

High

💵FCF Margin

-567.8%

Thin

⚖️P/S Ratio

-2.0x

Cheap

Otter Score

Weak

Trading Snapshot

Day Range: $3.80 – $3.85
52-Week Range: $3.19 – $21.40
Volume: $3.33B
Avg Volume: $2.86B
Shares Outstanding: 5.4M
Next Earnings: Oct 24, 2026

Fundamentals Snapshot

Annual Revenue: $16M
Last Q Revenue: $4M
P/E Ratio: -0.3
P/S Ratio: -2.0x
EPS (TTM): $-5.26
Dividend Yield: 0.00%

Why Investors Own NEUP

✓High-growth profile — revenue up +23.2% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$16M▲ +26.0% YoY

Gross Margin (TTM)

44.3%▲ +0.8% YoY

Operating Income (TTM)

$6M▲ +26.0% YoY

Free Cash Flow (TTM)

$1M▲ +26.0% YoY

About NEUPHORIA THERAPEUTICS INC

Neuphoria Therapeutics, Inc. is a biotechnology company currently advancing treatments through clinical trials. Its core mission involves pioneering therapies specifically engineered to address the intricate requirements of individuals living with neuropsychiatric disorders. The company was established on December 23, 2024, and its main corporate offices are located in Burlington, Massachusetts.

🦦